The power of combinations in blood cancers
Drug Target Review
NOVEMBER 6, 2023
These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers. 2015);126(1):9-16. 2015);126(4):454-462. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Let's personalize your content